In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

FOPO nets $90.8mm for Sequenom

Executive Summary

In a follow-on public offering, Sequenom Inc. (diagnostic testing and genetic analysis systems) has netted $90.8mm by selling 16.1mm shares (including the overallotment) at $6. Part of the proceeds will be specifically used for validation studies of the company's Trisomy 21 DNA test, which assesses pregnant women who are at a high risk for carrying a fetus with the chromosomal abnormality.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register